title: The effect of renal administration of a selective cyclooxygenase-2 inhibitor or stable prostaglandin I2 analog on the progression of sclerotic glomerulonephritis in rats.
abstract: METHODS
  There is increasing evidence that a change in glomerular hemodynamics may promote the development of glomerulosclerosis. In this study, we focused on the pharmacological effects of 2 contrasting agents, etodolac, a preferential cyclooxygenase-2 inhibitor, and beraprost sodium (BPS), a prostaglandin I(2) analog, delivered renally, on the disease course of progressive anti-Thy-1 (ATS) glomerulonephritis.
  
  
  RESULTS
  Intravital microscopic analysis showed that the diameters of glomerular capillaries and glomerular blood flow in unilaterally nephrectomized (Nx) rats treated locally with BPS were significantly increased, as compared to those of Nx rats treated locally with normal saline (NS) or etodolac. We then examined the effects of BPS and etodolac on the course of progressive glomerulosclerosis. Mesangial cell proliferation, adhesion of glomerular capillary tufts and crescent formation in the BPS-treated group appeared to be more severe compared to the ATS + NS and the ATS + etodolac groups. Scoring of mesangial proliferation and glomerulosclerosis revealed that local BPS treatment significantly worsened glomerular pathology. At day 28, there were significant differences in blood flow between the ATS + etodolac group and both the ATS + NS and ATS + BPS groups, indicating that local treatment with etodolac enhanced the recovery of glomerular circulation.
  
  
  CONCLUSIONS
  This study provides hemodynamic-based evidence showing that disturbance of intraglomerular microcirculation is a critical marker for progressive glomerulonephritis.
authors.affiliation: Department of Cellular Physiology, Institute of Nephrology, Graduate School of Medical and Dental Sciences, Niigata University, 1-757 Asahimachi-dori, Niigata, 951-8510, Japan.
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Nozawa
authors.forename: Ayako
authors.initials: A
authors.lastname: Sato
authors.forename: Hoglan
authors.initials: H
authors.lastname: Piao
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Morioka
authors.forename: Ichiei
authors.initials: I
authors.lastname: Narita
authors.forename: Takashi
authors.initials: T
authors.lastname: Oite
mesh_terms: D000818:Animals; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology*; D018450:Disease Progression; D011464:Epoprostenol / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D017308:Etodolac / Q000494:pharmacology / Q000627:therapeutic use*; D005920:Glomerular Mesangium / Q000187:drug effects* / Q000473:pathology; D005921:Glomerulonephritis / Q000188:drug therapy* / Q000473:pathology; D007518:Isoantibodies; D007678:Kidney Glomerulus / Q000098:blood supply / Q000187:drug effects / Q000473:pathology*; D051381:Rats; D017208:Rats, Wistar
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D007518:Isoantibodies; C035678:anti-Thy antibody; D017308:Etodolac; C048081:beraprost; D011464:Epoprostenol